Please ensure Javascript is enabled for purposes of website accessibility

Could Alnylam Pharmaceuticals Change Medicine as We Know It?

By Motley Fool Staff - May 31, 2016 at 7:22AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A revolutionary way of approaching disease treatment could spell massive gains for early investors.

Alnylam Pharmaceuticals' (ALNY 1.65%) deep pipeline is far superior to those of its competitors in the RNAi drug development space. But does this treatment mechanism work? Without an approved drug on the market, it's hard to be sure. What we do know, though, is that if it is successful, the opportunity is huge. Find out what's going on at Alnylam in this clip of Industry Focus: Healthcare.

A transcript follows the video.

This podcast was recorded on March 10, 2016, and was released on May 18, 2016.

Max Macaluso: Alnylam is the most prominent example of a company working in this space. It's a leader in this area of research. It has a $5 billion market cap. It's a very exciting biotech to watch, but it doesn't currently have any drugs on the market. It has two programs in phase 3 development, the rest of its assets are in phase 2 or earlier. But, it does have a very deep pipeline of therapeutics that could have huge market potential. I think, for investors, the focus at this stage is less about the market opportunity and more about whether or not they can get a drug approved by the FDA in this drug class. If it's able to do that, it can basically just create a brand-new type of therapeutic that we just haven't seen before.

Kristine Harjes: Yeah, and, unfortunately, you're going to have to just sit tight on that -- the company's not expected to file its first application until 2017. So, we're looking at maybe seeing approval in 2018. The company itself is not expected to be profitable until at least 2020. So, definitely a bit of a waiting game right now. But I think you're totally right that if we were to see even a single approval, it would go a long way to validating this entire class of drugs, and the rest of the company's pipeline.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Alnylam Pharmaceuticals, Inc. Stock Quote
Alnylam Pharmaceuticals, Inc.
$148.25 (1.65%) $2.40

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.